Please login to the form below

Not currently logged in
Email:
Password:

neurology

This page shows the latest neurology news and features for those working in and with pharma, biotech and healthcare.

Novartis files for approval of MS drug in EU, US

Novartis files for approval of MS drug in EU, US

In the EXPAND study presented at this year’s American Academy of Neurology (AAN) conference, siponimod showed a 14-20% reduced risk of disability progression in SPMS compared to placebo at

Latest news

More from news
Approximately 5 fully matching, plus 126 partially matching documents found.

Latest Intelligence

  • Tackling a formidable foe Tackling a formidable foe

    Ali-Frederic Ben-Amor, Vice President, Global Medical Affairs for Neurology &Immunology, Merck. ... Ali-Frederic Ben-Amor, Vice President, Global Medical Affairs for Neurology &Immunology, Merck, epitomises the field’s passion and refusal to take a

  • A quest for innovative solutions A quest for innovative solutions

    Ecosystem. “I have the most beautiful job in the company because my team and I are exposed to the change externally,” says Erik Janssen, UCB’s head of innovative solutions, Neurology

  • The good, the bad and the ugly The good, the bad and the ugly

    Biogen was the largest seller in the CNS market in 2017 and this is forecast to continue,” says Rahael Maladwala, analyst, neurology and ophthalmology, GlobalData. ... Neurology experienced slow growth, largely because few diseases are very well

  • Deal Watch October 2016 Deal Watch October 2016

    $330m. Neurology 2016. Aspen. 5 anesthetics. $770m royalties. $592m. 1.3. Neurology 2014. ... Lilly. AZD3293. $500 profit share. Neurology 2012. Impax US. Zomig US.

  • Deal Watch August 2016 Deal Watch August 2016

    So the product, which is an orphan drug, ended up in the portfolio of a $10bn company focussed on GI, dermatology and neurology and which was under investigation by the SEC

More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 30 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 11 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics